Flaptekst

Diabetes mellitus (DM) is metabolic disorders characterized by hyperglycaemia;
which may occurs due the imbalance between insulin secretion and insulin resistance. WHO has
reported at about 422 million populations is suffering from diabetes and more than 271
million new people will be diabetic by 2045. Around 61.2 million public are diabetic and
it is estimated to augment to 101.2 million by 2030 in India . At year basis,
it is estimated that approximately 2.5% -15% of world-wide health's budget is invested on DM and
Diabetic Foot ulcers (DFU) are the major part of this investment. The WHO also reports that
diabetic patient has a 25% of life risk to developing DFU .The main concern
is for elder group because this group is more prone to DFU leading to abscess and osteomyelitis. The DFU is one of the chronic diseases that decrease the quality life and becomes major cause of patient hospitalization and at last morbidity .The DFU patients mortality is double than a non DFU diabetic person. The occurrence rate of foot ulcers or infection among diabetic population has reached from 3% to 13% globally . Somewhere in the world, it is estimated that at every 30 sec . one lower limb is surgically removed and around 50-70% of amputations are due to diabetic wounds.


Diabetic foot ulcer is a common complication of diabetes that affects approximately 15% of individuals with the condition. The ulcer can lead to amputation, infections, and reduced quality of life. Traditional treatment methods such as dressing, antibiotics, and debridement have limited effectiveness, and there is a need for more effective treatment options.


The novel topical drug delivery system for the management of diabetic foot ulcers is a new approach that aims to address the limitations of traditional treatment methods. The system involves the use of a specially formulated gel that contains insulin and other growth factors.


The gel is applied directly to the ulcer, and the active ingredients are gradually released over time, promoting healing and reducing inflammation. The system also includes a monitoring device that measures the pH of the wound, allowing for real-time adjustments to the treatment plan.


The novel topical drug delivery system has several advantages over traditional treatment methods. It delivers the medication directly to the site of the wound, ensuring maximum effectiveness. The gradual release of the medication also reduces the risk of side effects.


Additionally, the monitoring device allows for personalized treatment plans and can help healthcare providers make more informed decisions about patient care. Overall, the novel topical drug delivery system has the potential to significantly improve the management of diabetic foot ulcers, leading to better outcomes for patients.